Troglitazone (TGZ, brand name: Rezulin and Prelay) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, which was developed by Daiichi Sankyo and approved for the US market for the treatment of Type II diabetes mellitus. The drug is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise, and was not indicated as initial therapy in patients with type 2 diabetes. This drug was withdrawn from the UK market due to liver toxicity. It was removed from the US market in 2000, only 3 years after its introduction and from Japan, shortly afterward. In addition, was conducted a clinical trial for the treatment of patients with advanced liposarcoma by using troglitazone, but the positive result wasn’t obtained. It was shown, that in case of cancer cells troglitazone acted independently of PPAR gamma, by up-regulation of early growth response-1 (Egr-1). Egr-1 transcription factor has been linked to apoptosis and shown to be activated by extracellular signal-regulated kinase (ERK).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10691680 |
780.0 nM [EC50] | ||
Target ID: P18146 Gene ID: 1958.0 Gene Symbol: EGR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12475986 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | PRELAY Approved UsePrelay is indicated to improve glycemic control in patients with type 2 diabetes mellitus as an adjunct to diet and exercise in combination with (not substituted for): · A sulfonylurea drug for patients who are not adequately controlled with a sulfonylurea alone or, · A sulfonylurea drug together with metformin for patients who are not adequately controlled with the combination of a sulfonylurea and metformin or, · Insulin in patients who are not adequately controlled with insulin alone. Prelay is not indicated as initial therapy in patients with type 2 diabetes Launch Date8.5449599E11 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. | 2000 Apr |
|
Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. | 2000 Aug |
|
Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone. | 2000 Dec |
|
Enhancing effect of troglitazone on porcine adipocyte differentiation in primary culture: a comparison with dexamethasone. | 2000 Dec |
|
Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. | 2000 Dec |
|
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats. | 2000 Dec 15 |
|
Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene. | 2000 Jul |
|
Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. | 2000 Jul 1 |
|
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. | 2000 Jul 18 |
|
Inhibitory effect of troglitazone on TNF-alpha-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells. | 2000 Jun |
|
Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. | 2000 May |
|
Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. | 2000 May |
|
Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. | 2000 May 19 |
|
Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. | 2000 May-Jun |
|
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. | 2000 Oct 1 |
|
Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes. | 2000 Oct 27 |
|
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. | 2000 Sep 8 |
|
Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat. | 2001 |
|
Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. | 2001 Apr |
|
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. | 2001 Apr 13 |
|
Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. | 2001 Apr 6 |
|
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. | 2001 Feb |
|
Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. | 2001 Feb |
|
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. | 2001 Jan |
|
The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. | 2001 Jan |
|
Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. | 2001 Jan 26 |
|
Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? | 2001 Jul |
|
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. | 2001 Mar |
|
Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. | 2001 Mar |
|
Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells. | 2001 Mar 9 |
|
Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. | 2001 May |
|
Troglitazone induces GLUT4 translocation in L6 myotubes. | 2001 May |
|
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. | 2001 May |
|
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. | 2001 Nov |
|
Regulation of the glyoxalase pathway in human brain microvascular endothelium: effects of troglitazone and tertiary butylhydroperoxide. | 2002 |
|
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. | 2002 Apr |
|
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. | 2002 Dec |
|
Receptor-dependent regulation of the CYP3A4 gene. | 2002 Dec 27 |
|
Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. | 2002 Feb 1 |
|
Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. | 2002 Jan |
|
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. | 2002 Jan 11 |
|
Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. | 2002 Jul |
|
Effects of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane (p,p'-DDT) on 3T3-L1 and 3T3-F442A adipocyte differentiation. | 2002 Mar 1 |
|
Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. | 2002 May 28 |
|
Effects of leptin, troglitazone, and dietary fat on stearoyl CoA desaturase. | 2002 Oct 11 |
|
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. | 2003 Apr |
|
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. | 2003 Feb |
|
Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. | 2003 Feb 21 |
|
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. | 2003 Mar 20 |
|
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. | 2003 Mar 24 |
Sample Use Guides
Prelay (TROGLITAZONE tablet) should be taken with a meal.
Combination Therapy:
Sulfonylureas: Prelay in combination with a sulfonylurea should be initiated at 200 mg once daily. The current sulfonylurea dose should be continued upon initiation of Prelay therapy. For patients not responding adequately, the Rezulin dose should be increased at 2 to 4 weeks. The maximum recommended dose is 600 mg once daily. The dose of sulfonylurea may require lowering to optimize therapy.
Metformin: For patients not responding adequately to metformin and sulfonylurea therapy, 400 mg daily of Prelay may be added.
Insulin: The current insulin dose should be continued upon initiation of Prelay therapy. Prelay therapy should be initiated at 200 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of Prelay should be increased after approximately 2 to 4 weeks. The usual dose of Prelay is 400 mg once daily. The maximum recommended daily dose is 600 mg. It is recommended that the insulin dose be decreased by 10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in patients receiving concomitant insulin and Prelay. Further adjustments should be individualized based on glucose-lowering response.
Patients With Renal Insufficiency: Dose adjustment in patients with renal insufficiency is not required
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16374840
Human HCC cell lines Huh7 and Hep3B were cultured in the presence or absence of troglitazone. Cell growth was determined via WST-1 assay, proliferation by cell cycle analysis and proliferating cell nuclear antigen (PCNA) Western blotting, and apoptosis by flow cytometry and TUNEL. In cultures of Hep3B and Huh7 cells, basal expression of PPARgamma was relatively low, but troglitazone caused dose-dependent induction of PPARgamma expression.
Substance Class |
Mixture
Created
by
admin
on
Edited
Thu Jul 06 00:03:57 UTC 2023
by
admin
on
Thu Jul 06 00:03:57 UTC 2023
|
Record UNII |
I66ZZ0ZN0E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1934
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
||
|
WHO-ATC |
A10BG01
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
||
|
LIVERTOX |
NBK548142
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
||
|
WHO-VATC |
QA10BG01
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
||
|
NCI_THESAURUS |
C98241
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB11332MIG
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
I66ZZ0ZN0E
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
M11218
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00197
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
C1522
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
CHEMBL408
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
DTXSID8023719
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
C057693
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
TROGLITAZONE
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
5591
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
9753
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
72610
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | RxNorm | ||
|
2767
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
6851
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
GG-89
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
97322-87-7
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY | |||
|
2693
Created by
admin on Thu Jul 06 00:03:57 UTC 2023 , Edited by admin on Thu Jul 06 00:03:57 UTC 2023
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> INDUCER |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
FECAL; PLASMA; URINE
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||